EyePoint Inc
EYPTHealthcare|Biotechnology|USA
$14.72
-0.12 (-0.81%)
Tangible Book
$2.76
Clinical Trials (20)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05191706 Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract | Cataract | P4 | Recruiting | 60 | RCT, Open-label | Dexamethasone, Prednisolone Acetate Ophthalmic |
| NCT07449923 CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | Diabetic Macular Edema, DME | P3 | Recruiting | 240 | RCT, Double-blind | EYP-1901, Aflibercept (2.0 mg) |
| NCT06683742 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | Wet Age Related Macular Degeneration, wAMD | P3 | Active | 400 | RCT, Double-blind | EYP-1901, Aflibercept (2.0 mg) |
| NCT07449936 COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | Diabetic Macular Edema, DME | P3 | Recruiting | 240 | RCT, Double-blind | EYP-1901, Aflibercept (2.0 mg) |
| NCT06668064 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | Wet Age Related Macular Degeneration, wAMD | P3 | Active | 400 | RCT, Double-blind | EYP-1901, Aflibercept (2.0 mg) |
| NCT04781335 "A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation" | Cataract | P4 | Completed | 25 | Single-blind | Dexycu, Standard of Care post operative eye drops (steroid, antibiotic, NSAID) |
| NCT02748512 Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis | Non-Infectious Uveitis | P3 | Completed | 26 | RCT, Single-blind | FAI Insert administered using the Mk II inserter, FAI Insert administered using the Mk I inserter |
| NCT05550363 A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2) | Cataract | P3 | Withdrawn | — | RCT, Double-blind | Dexycu |
| NCT01694186 Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert | Non-Infectious Uveitis | P3 | Completed | 129 | RCT, Double-blind | FAI insert, Sham injection |
| NCT05070728 Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert | Uveitis, Uveitis, Posterior | P3 | Terminated | 12 | RCT, Double-blind | Sham Injector, FAI Insert |
| NCT05550350 A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery | Cataract | P3 | Withdrawn | — | RCT, Double-blind | Dexycu |
| NCT02746991 Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis | Posterior Uveitis, Intermediate Uveitis | P3 | Completed | 153 | RCT, Double-blind | Sham Injection, FAI Insert |
| NCT05383209 Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR) | Nonproliferative Diabetic Retinopathy | P2 | Completed | 77 | RCT, Double-blind | EYP-1901 |
| NCT03197870 The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) | Nonproliferative Diabetic Retinopathy | P2 | Completed | 167 | RCT, Double-blind | AKB-9778, Placebo |
| NCT06099184 Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) | Diabetic Macular Edema | P2 | Completed | 27 | RCT, Single-blind | EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph |
| NCT04511650 Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019 | COVID-19, Acute Respiratory Distress Syndrome (ARDS) | P2 | Terminated | 31 | RCT, Double-blind | Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution |
| NCT04405245 Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma | Ocular Hypertension, Primary Open Angle Glaucoma | P2 | Completed | 194 | RCT, Double-blind | Latanoprost ophthalmic solution, AKB-9778 4%, Placebo |
| NCT05381948 Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) | Wet Age-related Macular Degeneration | P2 | Completed | 161 | RCT, Double-blind | EYP-1901, Aflibercept 2mg/0.05mL Inj,Oph |
| NCT04747197 First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD) | Wet Age-related Macular Degeneration | P1 | Completed | 17 | Open-label | EYP-1901 |
| NCT04290676 DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001 | Cataract | Completed | 527 | — | DEXYCU (dexamethasone intraocular suspension) 9%. |